Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome

doi:10.1016/j.tripleo.2010.01.006

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology

Volume 109, Issue 6, June 2010, Pages 844-850

https://doi.org/10.1016/j.tripleo.2010.01.006 Get rights and content

Objective

The objective of this study was to investigate the level of Toll-like receptors (TLRs) 7, 8, and 9 in peripheral mononuclear blood cells (PMBCs) from patients with primary Sjögren's syndrome (pSS) and whether TLR7 and 9 exist in the parotid glands of pSS patients.

Methods

TLR7, 8, and 9 mRNA levels in PMBC from 37 pSS patients and 24 controls were determined using real-time polymerase chain reaction. TLR7- and TLR9-positive cells in parotid glands from 20 pSS patients and 10 controls were observed using immunofluorescence and immunohistochemistry, respectively. Statistical analysis was performed by Student t test.

Results

TLR7 and TLR9 mRNA levels were 2.17- and 2.33-fold higher in pSS patients than control subjects, respectively (P < .05), whereas TLR8 levels were not. TLR7- and TLR9-positive cells of the pSS group were localized in the epithelial islands, lymphocytes, and ductal epithelial cells of the parotid glands and were more abundant than the TLR7- and TLR9-positive cells that were only localized to the ductal epithelial cells of parotid glands (P < .05).

Conclusion

TLR7 and TLR9 mRNA levels are up-regulated in the PMBC of pSS patients, and TLR7- and TLR9-positive cells exist in the epithelial islands, lymphocytes, and ductal epithelial cells of the parotid glands of individuals affected by pSS, but are limited to the ductal epithelial cells of controls.

Section snippets

Subjects

From February 2006 to August 2006, 37 patients with pSS and 24 control subjects were recruited from the Department of Oral and Maxillofacial Surgery, Ninth Hospital, School of Medicine, Shanghai Jiao Tong University, to participate in the study. The study protocol was approved by the Committee of Ethics, Faculty of Medicine, Shanghai Jiao Tong University. Informed consent was obtained from all subjects. All patients with pSS (36 women and 1 man; age range 23 to 70 years [mean 49.00 ± 12.74

Up-regulated TLR7 and TLR9 mRNA levels in PMBC with pSS

Using real-time PCR, we found that the mean value of −ΔΔCt of TLR7 with pSS was significantly higher (6.87 ± 1.29) compared with 5.75 ± 1.05 in the control blood samples (P = .0008). The ratio of TLR7 mRNA in the pSS group to the control group was 2.17 (Fig. 1, A, and 2). The mean value of −ΔΔCt of TLR8 with pSS was 8.62 ± 1.89 compared with 9.18 ± 1.46 in control samples. The ratio of TLR8 levels in the pSS group to the control group (Fig. 1, B, and 2) was 0.68 (P = .223). The mean value of

Discussion

TLR expression has been implicated in diverse cell types such as airway and gut epithelial cells, B cells, mast cells, natural killer (NK) cells, dendritic cells (DCs), regulatory T cells, macrophages, monocytes, neutrophils, and endothelial cells. The expression of TLR in diverse cell types illustrates their distinct functional roles in innate as well as adaptive immune responses. The diversity and specificity in the recognition of a wide range of molecular motifs and chemical structures by

References (30)

P.J. Venables
Sjögren's syndrome
Best Pract Res Clin Rheumatol
(2004)
R.I. Fox
Sjögren's syndrome
Lancet
(2005)
M. Takei et al.
The possible etiopathogenic genes of Sjögren's syndrome
Autoimmun Rev
(2005)
P.N. Moynagh
TLR signaling and activation of IRFs: revisiting old friends from the NF-κB pathway
Trends Immunol
(2005)
A.G. Bowie et al.
The role of Toll-like receptors in the host response to viruses
Mol Immunol
(2005)
L.Y. Zheng et al.
Expression of interferon regulatory factor 1, 3, 7 in primary Sjögren's syndrome
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
(2009)
R. Manthorpe
Sjögren's syndrome criteria
Ann Rheum Dis
(2002)
C. Vitali et al.
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group
Ann Rheum Dis
(2002)
A.I. Bolstad et al.
Genetic aspects of Sjögren's syndrome
Arthritis Res
(2002)
A. Hansen et al.
Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy
Curr Opin Rheumatol
(2005)

J.E. Gottenberg et al.

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

Proc Natl Acad Sci U S A

(2006)

R.I. Fox et al.

Update in Sjögren's syndrome

Curr Opin Rheumatol

(2000)

S. Sugai

Hepatitis C virus and Sjögren's syndrome

Intern Med

(2005)

P. Youinou et al.

Viruses contribute to the development of Sjögren's syndrome

Clin Exp Immunol

(2005)

A. Triantafyllopoulou et al.

Evidence for Coxsackievirus infection in primary Sjögren's syndrome

Arthritis Rheum

(2004)

Cited by (63)

Targeting plasma cells in systemic autoimmune rheumatic diseases – Promises and pitfalls
2023, Immunology Letters
Plasma cells are the antibody secretors of the immune system. Continuous antibody secretion over years can provide long-term immune protection but could also be held responsible for long-lasting autoimmunity in case of self-reactive plasma cells. Systemic autoimmune rheumatic diseases (ARD) affect multiple organ systems and are associated with a plethora of different autoantibodies. Two prototypic systemic ARDs are systemic lupus erythematosus (SLE) and Sjögren's disease (SjD). Both diseases are characterized by B-cell hyperactivity and the production of autoantibodies against nuclear antigens. Analogues to other immune cells, different subsets of plasma cells have been described. Plasma cell subsets are often defined dependent on their current state of maturation, that also depend on the precursor B-cell subset from which they derived. But, a universal definition of plasma cell subsets is not available so far. Furthermore, the ability for long-term survival and effector functions may differ, potentially in a disease-specific manner. Characterization of plasma cell subsets and their specificity in individual patients can help to choose a suitable targeting approach for either a broad or more selective plasma cell depletion. Targeting plasma cells in systemic ARDs is currently challenging because of side effects or varying depletion efficacies in the tissue. Recent developments, however, like antigen-specific targeting and CAR-T-cell therapy might open up major benefits for patients beyond current treatment options.
Hsa_circ_0008301 as a potential biomarker of disease activity for primary Sjogren's syndrome: Increased expression in peripheral blood of patients with primary Sjogren's syndrome
2022, International Immunopharmacology
To explore the expression level, association with disease activity and clinical significance of hsa_circ_0008301 in the peripheral blood of patients with primary Sjögren's syndrome (pSS).
We selected 70 pSS patients hospitalized under the Rheumatology service line at the General Hospital of Ningxia Medical University from September 2018 to June 2021 as the disease group, in which general data and clinical indicators were collected. Fifty-three patients with healthy physical examinations for the same period were selected as the healthy control group, and 32 patients with non-pSS rheumatic diseases were selected as the disease control group. We collected peripheral blood samples and used fluorescence quantitative PCR to detect the expression level of hsa_circ_0008301. In addition, we analyzed the association of the expression level of hsa_circ_0008301 with the clinical characteristics and disease activity of pSS patients. A receiver operating characteristic curve was used to evaluate the diagnosis and the disease activity value of hsa_circ_0008301 in patients with pSS. Meanwhile, we analyzed the differential expression of hsa_circ_0008301 in 24 pSS patients selected from the disease group before and after treatment.
The relative expression of hsa_circ_0008301 in the peripheral blood of pSS patients was significantly higher than that in the control groups including healthy control group and disease control group. The expression level of hsa_circ_0008301 was high in pSS patients with a course of disease ≥ 10 years, fatigue symptoms, platelets < 100*10^9/L, erythrocyte sedimentation rate ≥ 50 mm/h, immunoglobulin IgG > 16 g/L, complement C3 < 0.9 g/L, ESSDAI score ≥ 5 and positively correlated with the above groups. Furthermore, ROC analysis showed that hsa_circ_0008301 was statistically significant between pSS patients and healthy controls. We selected patients from the disease group before and after treatment and showed that the expression level of hsa_circ_0008301 decreased significantly after treatment, compared with before. The area under the curve (AUC) was 0.825 (95% CI: 0.754 ∼ 0.897; P < 0.0001). The AUC of hsa_circ_0008301 in pSS patients and the disease control group was 0.673 (95% CI: 0.563 ∼ 0.782; P = 0.005), the sensitivity was 40.00%, the specificity was 93.70%, the optimal truncation value was > 0.0420, and the maximum Youden index was 0.337. In addition, ROC analysis revealed that hsa_circ_0008301 was statistically significant between disease-active patients and stable patients. The AUC value was 0.681 (95% CI: 0.553 ∼ 0.809; P = 0.010), the sensitivity was 65.90%, the specificity was 72.40%, the optimal truncation value was > 0.0285, and the maximum Youden index was 0.383. ROC analysis indicated that hsa_circ_0008301 has some value in the diagnosis and disease activity of patients with pSS. Comparison of 24 pSS patients selected from the disease group before and after treatment showed that the expression level of hsa_circ_0008301 decreased significantly after treatment compared with before treatment (Z = − 4.257, P < 0.0001). ROC analysis indicated that hsa_circ_0008301 has some value in the diagnosis and disease activity of patients with pSS.
Hsa_circ_0008301 is expressed in higher levels in the peripheral blood of patients with pSS, which is related to the disease activity. It may be involved in the occurrence and development of pSS and may have a potential biomarker for the disease.
Dysfunctional mitochondria as critical players in the inflammation of autoimmune diseases: Potential role in Sjögren's syndrome
2021, Autoimmunity Reviews
Relevant reviews highlight the association between dysfunctional mitochondria and inflammation, but few studies address the contribution of mitochondria and mitochondria-endoplasmic reticulum (ER) contact sites (MERCs) to cellular homeostasis and inflammatory signaling. The present review outlines the important role of mitochondria in cellular homeostasis and how dysfunctional mitochondrion can release and misplace mitochondrial components (cardiolipin, mitochondrial DNA (mtDNA), and mitochondrial formylated peptides) through multiple mechanisms. These components can act as damage-associated molecular patterns (DAMPs) and induce an inflammatory response via pattern recognition receptors (PRRs). Accumulation of damaged ROS-generating mitochondria, accompanied by the release of mitochondrial DAMPs, can activate PRRs such as the NLRP3 inflammasome, TLR9, cGAS/STING, and ZBP1. This process would explain the chronic inflammation that is observed in autoimmune diseases such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), type I diabetes (T1D), and Sjögren’s syndrome.
This review also provides a comprehensive overview of the importance of MERCs to mitochondrial function and morphology, cellular homeostasis, and the inflammatory response. MERCs play an important role in calcium homeostasis by mediating the transfer of calcium from the ER to the mitochondria and thereby facilitating the production of ATP. They also contribute to the synthesis and transfer of phospholipids, protein folding in the ER, mitochondrial fission, mitochondrial fusion, initiation of autophagosome formation, regulation of cell death/survival signaling, and regulation of immune responses. Therefore, alterations within MERCs could increase inflammatory signaling, modulate ER stress responses, cell homeostasis, and ultimately, the cell fate.
This study shows severe ultrastructural alterations of mitochondria in salivary gland cells from Sjögren’s syndrome patients for the first time, which could trigger alterations in cellular bioenergetics. This finding could explain symptoms such as fatigue and malfunction of the salivary glands in Sjögren’s syndrome patients, which would contribute to the chronic inflammatory pathology of the disease. However, this is only a first step in solving this complex puzzle, and several other important factors such as changes in mitochondrial morphology, functionality, and their important contacts with other organelles require further in-depth study. Future work should focus on detecting the key milestones that are related to inflammation in patients with autoimmune diseases, such as Sjögren´s syndrome.
Pathophysiologic role of Interleukin-33/ST2 in Sjögren's syndrome
2021, Autoimmunity Reviews
Interleukin-33 (IL-33) is a member of the IL-1 family and has dual functions as a nuclear factor as well as a cytokine. The pivotal role of IL-33 as an active player contributing to aberrant local and systemic damage has been highlighted in several inflammatory and autoimmune diseases. Primary Sjögren's syndrome (pSS) is an autoimmune disease characterized by dry eyes and mouth syndrome due to local dysfunctions of exocrine glands, but also accompanied with systemic manifestations. The pathophysiology of pSS has been advocated as a conjecture of activated B and T cells as well as the production of inflammatory cytokines and autoantibodies, driving epithelial tissue damage and disease progression. In pSS, IL-33 is released in the extracellular space from damaged salivary cells upon pro-inflammatory stimuli and/or dysfunction of epithelial barrier. Counter-regulatory mechanisms are initiated to limit the pro-inflammatory actions of IL-33 as portrayed by an increase in the decoy receptor for IL-33, the soluble form of ST2 (sST2). In pSS and associated diseases, the levels of IL-33 are significantly elevated in the serum or tears of patients. Mechanistically, IL-33 acts in synergy with IL-12 and IL-23 on NK and NKT cells to boost the production of IFN-γ contributing to inflammation. TNF-α, IL-1β and IFN-γ in turn further increase the activation of IL-33/ST2 pathway, thereby constituting a vicious inflammatory loop leading to disease exacerbation. IL-33/ST2 axis is involved in Sjögren's syndrome and opens new perspectives as therapeutic target of one of the culprits in the inflammatory perpetuation.
Autoimmune diseases and the role of Toll-like receptor-7 and -9 signaling cascades
2021, Translational Autoimmunity: Etiology of Autoimmune Diseases
Endosomal toll-like receptors such as TLR7 and TLR9 are often upregulated in autoimmune settings. Interestingly, studies in animal models have largely confirmed a dichotomous function of these two receptors, with TLR7 being pathogenic and TLR9 being protective. We here introduce these TLRs and discuss data supporting a role for each in five different autoimmune disorders based on both human and animal data. Furthermore, we present a comprehensive list of currently known agonists and antagonists of TLR7 and TLR9 activation and signaling, speculating on the potential use of these therapeutics in autoimmunity.
MiR-155 Negatively Regulates Anti-Viral Innate Responses among HIV-Infected Progressors
2023, Viruses

View all citing articles on Scopus

: This work was supported by the Science and Technology Commission of Shanghai (08DZ2271100) and the Shanghai Leading Academic Discipline Project (Project Number: S30206).

View full text

Oral medicineExpression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome

Objective

Methods

Results

Conclusion

Section snippets

Subjects

Up-regulated TLR7 and TLR9 mRNA levels in PMBC with pSS

Discussion

Best Pract Res Clin Rheumatol

Lancet

Autoimmun Rev

Trends Immunol

Mol Immunol

Oral Surg Oral Med Oral Pathol Oral Radiol Endod

Sjögren's syndrome criteria

Ann Rheum Dis

Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group

Ann Rheum Dis

Genetic aspects of Sjögren's syndrome

Arthritis Res

Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy

Curr Opin Rheumatol

Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome

Proc Natl Acad Sci U S A

Update in Sjögren's syndrome

Curr Opin Rheumatol

Hepatitis C virus and Sjögren's syndrome

Intern Med

Viruses contribute to the development of Sjögren's syndrome

Clin Exp Immunol

Evidence for Coxsackievirus infection in primary Sjögren's syndrome

Arthritis Rheum

Oral medicine
Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome